The Ministry of Ayush brought attention to a serious problem with deceptive ads for Ayush medications on August 9, 2024. Information from Prataprao Jadhav, the Minister of State for Ayush, states that 38,539 deceptive ads for Ayush products have been reported through the Pharmacovigilance program. The Ayush Oushadhi Gunvatta evam Uttpadan Samvardhan Yojana (AOGUSY), which is intended to oversee the security and caliber of Ayush medications, includes this scheme.
Jadhav confirmed that no complaints about the marketing of Ayush products without legitimate clinical trials had been received, despite the prevalence of deceptive advertisements. This implies that although deceptive marketing is rife, there aren’t any difficulties about the products’ actual marketability that have been brought to light. The focus on clinical trials highlights how crucial it is to make sure that goods are approved by science before going on sale, as this is essential to upholding public safety and confidence.
The Ministry of Ayush has asked State Drug Licensing Authorities and State Drug Controllers to put remedial measures in place in order to address the problem of deceptive ads. The purpose of these steps is to stop unsuitable ads from appearing in print and electronic media, including newspapers. The Ministry’s directive, which aims to stop misleading advertising techniques that can mislead consumers, shows a proactive commitment to regulation and enforcement.
The Department of Information and Broadcasting (MOIB) is in charge of television ads. When deceptive advertising for Ayush medications is detected, the MOIB is notified so that additional action can be taken. This cooperation between several government agencies demonstrates a multipronged approach to addressing the problem from multiple angles—making sure that advertisements follow legal requirements and that dishonest activities are swiftly addressed.
The Pharmacovigilance program, which is vital to the monitoring and assurance of the safety of Ayush medications, provides a larger framework for these endeavors. Through the program’s tracking of complaints and issues pertaining to medicine marketing, public health is protected and the integrity of the Ayush industry is upheld.
All things considered, the Ministry of Ayush’s activities show a continued dedication to improving the legal environment around Ayush products. In order to safeguard consumers and encourage the ethical marketing of Ayush medications, the government targets deceptive advertising and makes sure that clinical trial regulations are followed.
SOURCE :
THE PRINT
